latest news releases from the newsroom
SWsoft Acquires Sphera to Accelerate Software-as-a-Service Delivery
HERNDON, Va., Sept. 18, 2007 (PRIME NEWSWIRE) -- SWsoft, Inc. has acquired Sphera Corporation to accelerate the delivery of software-as-a-service (SaaS) solutions for consumers, businesses and service providers. SWsoft will merge Sphera with its automation software business unit that already powers tens of thousands of servers for businesses and service providers worldwide.
SOYO Group Inc.
SOYO Adds New Bluetooth 2.0 Headset to Its FreeStyler Product Line
ONTARIO, Calif., Sept. 18, 2007 (PRIME NEWSWIRE) -- SOYO Group Inc. (OTCBB:SOYO), an innovative provider of computer, consumer electronics and broadband telecommunications products, announced today the launch of their New FreeStyler(tm) 600 Bluetooth 2.0 Headset with EDR (Enhanced Data Rate) technology, which is compatible with multiple Bluetooth devices such as mobile phones, PDA's and PC's.
Website Pros, Inc.
1ShoppingCart Creates New State-of-the-Art eCommerce Platform
BARRIE, Ontario, Sept. 18, 2007 (PRIME NEWSWIRE) -- 1ShoppingCart, the online shopping cart and marketing application services provider, today releases the next generation of its eCommerce platform. 1ShoppingCart's team of developers spent 16 months rebuilding from scratch the company's already-successful platform, using the most advanced technologies available and drawing upon extensive customer feedback.
Samaritan Pharmaceuticals, Inc.
FDA Accepts Samaritan's Cushing's SP-6300 IND and Clears Phase II Study
LAS VEGAS, Sept. 18, 2007 (PRIME NEWSWIRE) -- Samaritan Pharmaceuticals, Inc. (AMEX:LIV), a developer of innovative drugs, is pleased to announce the U.S. Food and Drug Administration (FDA) has completed its regulatory review of Samaritan's IND (Investigational New Drug) application for Cushing's syndrome SP-6300 and declared it has not identified any deficiencies in its IND filing. Accordingly, Samaritan can proceed with its proposed Phase II clinical study of Cushing's syndrome SP-6300's efficacy in patients experiencing Hypercortisolism.